Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin R J Kolb

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
American Journal of Respiratory and Critical Care Medicine|June 23, 2011
Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace?Martin R J Kolb, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|November 3, 2017
A Switch in TGF-β Signaling Explains Contradictory Findings in Pulmonary Arterial HypertensionLaszlo Farkas, Martin R J Kolb
Respirology (Carlton, Vic.)|December 4, 2014
Drug development for chronic lung disease--mission impossible?Kjetil Ask, Martin R J Kolb
The Lancet. Respiratory Medicine|September 25, 2017
Personalised medicine for IPF: getting closer, but not there yetSeidai Sato, Martin R J Kolb
Respirology (Carlton, Vic.)|April 9, 2009
Respirology year-in-review 2008: basic scienceMartin R J Kolb, Ian Yang
American Journal of Respiratory and Critical Care Medicine|September 17, 2011
Idiopathic pulmonary fibrosis: the matrix is the messageMartin R J Kolb, Jack Gauldie
Idrugs : the Investigational Drugs Journal|May 1, 2010
Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosisSabina A Antoniu, Martin R J Kolb
American Journal of Respiratory and Critical Care Medicine|September 12, 2023
Reply to: Huang <i>et al.</i>Toyoshi Yanagihara, Kazuya Tsubouchi, Martin R J Kolb
Expert Opinion on Investigational Drugs|December 5, 2018
Therapeutic targets and early stage clinical trials for pulmonary fibrosisSeidai Sato, Toyoshi Yanagihara, Martin R J Kolb
The European Respiratory Journal|June 8, 2023
Endothelial cells in pulmonary fibrosis: more than a bystanderToyoshi Yanagihara, Christophe Guignabert, Martin R J Kolb
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
American Journal of Respiratory and Critical Care Medicine|June 23, 2011
Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace?Martin R J Kolb, Luca Richeldi
American Journal of Respiratory and Critical Care Medicine|November 3, 2017
A Switch in TGF-β Signaling Explains Contradictory Findings in Pulmonary Arterial HypertensionLaszlo Farkas, Martin R J Kolb
Respirology (Carlton, Vic.)|December 4, 2014
Drug development for chronic lung disease--mission impossible?Kjetil Ask, Martin R J Kolb
The Lancet. Respiratory Medicine|September 25, 2017
Personalised medicine for IPF: getting closer, but not there yetSeidai Sato, Martin R J Kolb
Respirology (Carlton, Vic.)|April 9, 2009
Respirology year-in-review 2008: basic scienceMartin R J Kolb, Ian Yang
American Journal of Respiratory and Critical Care Medicine|September 17, 2011
Idiopathic pulmonary fibrosis: the matrix is the messageMartin R J Kolb, Jack Gauldie
Idrugs : the Investigational Drugs Journal|May 1, 2010
Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosisSabina A Antoniu, Martin R J Kolb
American Journal of Respiratory and Critical Care Medicine|September 12, 2023
Reply to: Huang <i>et al.</i>Toyoshi Yanagihara, Kazuya Tsubouchi, Martin R J Kolb
Expert Opinion on Investigational Drugs|December 5, 2018
Therapeutic targets and early stage clinical trials for pulmonary fibrosisSeidai Sato, Toyoshi Yanagihara, Martin R J Kolb
The European Respiratory Journal|June 8, 2023
Endothelial cells in pulmonary fibrosis: more than a bystanderToyoshi Yanagihara, Christophe Guignabert, Martin R J Kolb
Pageof 4